search
Back to results

Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease (PROMISE)

Primary Purpose

COPD, Comorbidities and Coexisting Conditions

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
NuvoAir Clinical Service
Sponsored by
NuvoAir Medical PC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for COPD

Eligibility Criteria

30 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Have COPD, including emphysema and chronic bronchitis, per relevant COPD diagnostic codes in the past 2 years Are age ≥30 years Have access to a smartphone, cell phone, or landline telephone Exclusion Criteria: Do not have serious medical illness that would interfere with cooperation or understanding of instructions, including terminal illness, active substance abuse, or unstable mental illness or psychiatric condition Does not have severe uncompensated heart failure, acute cor pulmonale, clinically unstable pulmonary embolism, history of syncope related to forced expiration/cough, cerebral aneurysm, presence of pneumothorax. Is not pregnant or known intention to become pregnant within 12 months

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    NuvoAir Clinical service

    Standard Care

    Arm Description

    Patients with COPD receiving usual care plus NuvoAir clinical services.

    Propensity matched controls with COPD who receive usual care.

    Outcomes

    Primary Outcome Measures

    Moderate & Severe Exacerbations
    Rate of moderate and severe exacerbations of COPD, measured by the health insurer or provider's records.

    Secondary Outcome Measures

    Readmissions
    Rate of hospital readmission in 30 days following COPD related hospitalization
    Hospital days
    Median number of hospital days
    Cost of care
    Total cost of care as measured by insurer claims data

    Full Information

    First Posted
    July 13, 2023
    Last Updated
    July 13, 2023
    Sponsor
    NuvoAir Medical PC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05955482
    Brief Title
    Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease
    Acronym
    PROMISE
    Official Title
    PROMISE: Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 24, 2023 (Anticipated)
    Primary Completion Date
    July 2025 (Anticipated)
    Study Completion Date
    July 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    NuvoAir Medical PC

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a 12 month study of up to 500 people with COPD to determine if the NuvoAir clinical service leads to lower rates of severe COPD exacerbations, hospitalizations, emergency room visits, and total cost of care compared to a similar group that doesn't receive care from the NuvoAir clinical service.
    Detailed Description
    Description: The program will be a virtual (decentralized), pragmatic evaluation of an implementation of the NuvoAir Clinical service for patients with COPD residing in the United States of America and who are enrolled with one or more health insurers or providers supporting the program. The evaluation will be organized around two cohorts; Patients with an ICD10 code for COPD (in the health insurer's or provider's database); Who use the NuvoAir Clinical service vs those Who undergo standard care (matched control - no intervention) Each patient in the NuvoAir cohort will receive their routine clinical care from their primary care provider with the addition of the NuvoAir Clinical service. The NuvoAir Clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required. Each patient in the standard care cohorts will receive their routine clinical care from their healthcare provider as usual. Only anonymized data that is usually collected by their health insurer or provider will be subject to analysis, no additional data will be collected for the standard care cohort. NuvoAir and standard care cohorts will be matched on the basis of age, gender, disease severity (ICD10 code for COPD with a severe exacerbation of COPD in the previous 12 months), geographic place and period of entry into the program. The program period will include 1 year of active participation (for NuvoAir users) followed by 1 year of follow-up using health insurer or provider records. Objectives: To determine if use of the NuvoAir clinical service results in a lower rate and number of moderate and severe exacerbations of COPD, lower readmissions due to COPD exacerbation within a 30-day period following a COPD exacerbation, lower days in hospital and lower healthcare costs compared with the matched cohorts of standard care patients who do not use the NuvoAir clinical service. To determine if use of the NuvoAir results in reduced readmissions due to COPD during the 30-day period following an exacerbation, improved health status and improved adherence compared with prior to the program/baseline.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    COPD, Comorbidities and Coexisting Conditions

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Pragmatic evaluation of a clinical service using a prospective cohort comparison of intervention vs propensity matched controls.
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    500 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    NuvoAir Clinical service
    Arm Type
    Experimental
    Arm Description
    Patients with COPD receiving usual care plus NuvoAir clinical services.
    Arm Title
    Standard Care
    Arm Type
    No Intervention
    Arm Description
    Propensity matched controls with COPD who receive usual care.
    Intervention Type
    Other
    Intervention Name(s)
    NuvoAir Clinical Service
    Intervention Description
    The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
    Primary Outcome Measure Information:
    Title
    Moderate & Severe Exacerbations
    Description
    Rate of moderate and severe exacerbations of COPD, measured by the health insurer or provider's records.
    Time Frame
    12 months
    Secondary Outcome Measure Information:
    Title
    Readmissions
    Description
    Rate of hospital readmission in 30 days following COPD related hospitalization
    Time Frame
    30 days post admission
    Title
    Hospital days
    Description
    Median number of hospital days
    Time Frame
    12 months
    Title
    Cost of care
    Description
    Total cost of care as measured by insurer claims data
    Time Frame
    12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Have COPD, including emphysema and chronic bronchitis, per relevant COPD diagnostic codes in the past 2 years Are age ≥30 years Have access to a smartphone, cell phone, or landline telephone Exclusion Criteria: Do not have serious medical illness that would interfere with cooperation or understanding of instructions, including terminal illness, active substance abuse, or unstable mental illness or psychiatric condition Does not have severe uncompensated heart failure, acute cor pulmonale, clinically unstable pulmonary embolism, history of syncope related to forced expiration/cough, cerebral aneurysm, presence of pneumothorax. Is not pregnant or known intention to become pregnant within 12 months
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Eric Harker, MD
    Phone
    3037485781
    Email
    eric.harker@nuvoair.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jeffrey VanWormer, PHD
    Organizational Affiliation
    Marshfield Clinic
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease

    We'll reach out to this number within 24 hrs